Search

Your search keyword '"Cook, G"' showing total 174 results

Search Constraints

Start Over You searched for: Author "Cook, G" Remove constraint Author: "Cook, G" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
174 results on '"Cook, G"'

Search Results

2. UK Stakeholder Perspectives on Surrogate Endpoints in Cancer, and the Potential for UK Real-World Datasets to Validate Their Use in Decision-Making

3. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

4. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

7. Subgroups, hyperbolicity and cohomological dimension for totally disconnected locally compact groups

12. P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

13. 'No one's ever said anything about sleep': A qualitative investigation into mothers' experiences of sleep in children with epilepsy

14. Changing Agendas on Sleep, Treatment and Learning in Epilepsy (CASTLE) Sleep-E: a protocol for a randomised controlled trial comparing an online behavioural sleep intervention with standard care in children with Rolandic epilepsy

16. Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”

18. Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study

19. Examining the immunological effects of COVID-19 vaccination in patients with conditions potentially leading to diminished immune response capacity – the OCTAVE trial

20. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

21. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

22. Meer biodiversiteit op ons bord

26. Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE

28. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

30. Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’

31. Subgroups, hyperbolicity and cohomological dimension for totally disconnected locally compact groups.

36. P23  EM AGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.

38. Compositional zoning of the Otowi Member of the Bandelier Tuff, Valles caldera, New Mexico, USA.

39. 185 (PB-092) Poster - Cerenkov Luminescence Imaging and Flexible AutoRadiography – a first-in-human novel imaging study for intra-operative margin assessment in women undergoing breast-conserving surgery for cancer.

40. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma:A European Myeloma Network (EMN) Report Within the HARMONY Project

41. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

42. Automated extraction of body composition metrics from abdominal CT or MR imaging: A scoping review.

43. Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

44. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

45. Association between lung consolidation and serum amyloid-A and haptoglobin, and the potential of acute phase proteins to differentiate primary respiratory tract pathogens in calves.

46. New Modes of Practice: A Framework Analysis of School Nurses' Accounts of Working With Children and Young People During COVID-19.

48. The methodological challenges faced when conducting hydration research in UK care homes.

49. Prostate specific membrane antigen (PSMA) avid nonprostatic benign and malignant disease: a pictorial review.

50. Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.

Catalog

Books, media, physical & digital resources